Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party.
Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party.
复制标题
小细胞肺癌每周多种药物化疗与标准联合方案的比较：欧洲肺癌工作组进行的一项 III 期随机研究。
DOI：
--
复制
发表时间：
1993
影响因子：
45.3
通讯作者：
J. Michel
中科院分区：
文献类型：
--
作者：
J. Sculier;M. Paesmans;G. Bureau;G. Dabouis;P. Libert;G. Vandermoten;O. V. Cutsem;M. Berchier;Fernand Ries;J. Michel
PURPOSE
A randomized trial was conducted in patients with small-cell lung cancer (SCLC) to determine if survival can be improved by a weekly chemotherapy regimen combining various drugs.
PATIENTS AND METHODS
Two hundred twenty-three patients were randomized to receive either six courses of a multiple-drug combination (MDC) regimen (Adriamycin [ADR; doxorubicin; Farmitalia Carlo Erba, Milan, Italy] 25 mg/m2 intravenously [i.v.] on day 1; etoposide [VP16] 120 mg/m2 i.v. on day 1; cyclophosphamide [CPA] 500 mg/m2 i.v. on day 1; cisplatin 60 mg/m2 i.v. on day 8; vindesine [VDS] 3 mg/m2 i.v. on day 8; vincristine [VCR] 2 mg i.v. on day 15; methotrexate [MTX] 100 mg/m2 i.v. on day 15), or a standard chemotherapy (SC) regimen (ADR 50 mg/m2 i.v. on day 1; CPA 1 g/m2 i.v. on day 1; VP16 80 mg/m2 i.v. on days 1 to 3).
RESULTS
In 98 MDC-treated and 101 SC-treated assessable patients, we observed 69% and 62% objective responses rates, respectively. There was no significant difference in survival, with median durations and 2-year overall survival rates of 49 and 43 weeks and 8.5% and 7.9%, respectively. There was a significant increase in response rate in favor of MDC patients with limited disease (84% v 62%). Toxicity was tolerable, although SC was more hematotoxic, with 76% (v 59%) experiencing leukopenia and 17% (v 7%) experiencing thrombocytopenia (grades III and IV). If the cumulative doses received were nearly equal to the scheduled cumulative doses in both arms, the total relative dose-intensity (RDI) was significantly higher in the SC arm. The difference was due to increased treatment delays in the MDC arm.
CONCLUSION
Weekly MDC failed to improve survival rates in patients with SCLC.
ProMACE-CytaBOM 治疗非霍奇金淋巴瘤的不利组织学：西南肿瘤小组的一项全组研究。
DOI：
10.1200/jco.1990.8.12.1951
发表时间：
1990
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Miller,TP;Dahlberg,S;Weick,JK;Files,JC;Eyre,HJ;Pendergrass,KB;Fisher,RI
通讯作者：
Fisher,RI
影响因子：
45.3
作者：
KWAK, LW;HALPERN, J;HORNING, SJ
通讯作者：
HORNING, SJ
影响因子：
9.6
作者：
ALBAIN, KS;CROWLEY, JJ;LIVINGSTON, RB
通讯作者：
LIVINGSTON, RB